

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

CLARIFICATION ANNOUNCEMENT IN RELATION TO RESIGNATION OF NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Reference is made to the announcement of Ascentage Pharma Group International (the “**Company**”) dated March 31, 2021 in relation to the resignation of a non-executive Director and the appointment of an independent non-executive Director (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board wishes to clarify that, due to an inadvertent error, the final paragraph on page 2 of the Announcement should read as follows (with the corrections underlined for ease of reference):

“Dr. Sidransky has entered into a letter of appointment with the Company for a term of service commencing on March 31, 2021 and ending on the date of the AGM. Dr. Sidransky will not receive any remuneration from the Company pursuant to this letter of appointment. Subject to the approval by the Shareholders of the re-election of Dr. Sidransky at the AGM, Dr. Sidransky will enter into a new letter of appointment with the Company for a term of three years commencing on the date of his re-election. Pursuant to this new letter

of appointment, Dr. Sidransky will receive remuneration comprising US\$60,000 in cash per annum, together with a one-off grant of such number of restricted share units to be granted under the restricted share unit scheme of the Company adopted by the Board on February 2, 2021 with the value of the underlying shares on the date of grant being US\$60,000 during the term of service. Such remuneration (i) has been recommended by the remuneration committee of the Company and proposed by the Board with reference to, among other things, (a) his duties and responsibilities within the Company; (b) the prevailing market conditions; and (c) the continuous expansion of the business scale and continuously heightening requirements on corporate governance of the Company over recent years, and (ii) is also subject to the approval of the Shareholders at the AGM.”

Save for the aforesaid, all the information in the Announcement remains true and accurate.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People’s Republic of China, April 1, 2021

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent nonexecutive Directors.